Cancer NetworkOriginal article
<![CDATA[Namodenoson Yields Durable Survival Outcomes in Pretreated Pancreatic Cancer]]>
Phase 2positivenamodenosonPositive
AI Analysis
Summary
Updated phase 2a data for namodenoson demonstrated durable survival outcomes in heavily pretreated patients with advanced pancreatic cancer. The positive results support further development of this candidate in this difficult-to-treat indication.
Clinical Trial Data
Phase
2a
Primary Endpoint
Met
Outcome Details
durable survival outcomes in heavily pretreated patients with advanced pancreatic cancer
Importance:6/10
Sentiment:
0.65
oncologypancreatic cancerphase 2adata readout
Read the original article
Published by Cancer Network on July 1, 2026 3:00 PM